Recombinant human FGF-2 therapy for osteonecrosis of the femoral head: 5-year follow-up

To evaluate the 5-year outcomes from the prospective study of recombinant human FGF-2 (rhFGF-2) for osteonecrosis of the femoral head (ONFH). Ten patients (average age 39.8 years) with nontraumatic, precollapse ONFH were percutaneously administered with 800 μg rhFGF-2 contained in gelatin hydrogel....

Full description

Saved in:
Bibliographic Details
Published in:Regenerative medicine 2020-11, Vol.15 (11), p.2261-2271
Main Authors: Kuroda, Yutaka, Ito-Ihara, Toshiko, Abe, Hiroyasu, Nankaku, Manabu, Okuzu, Yaichiro, Kawai, Toshiyuki, Goto, Koji, Matsuda, Shuichi
Format: Article
Language:English
Subjects:
Adult
Alcohol use
avascular necrosis
bone regeneration
Classification
Clinical outcomes
clinical trial
Clinical trials
core decompression
Femur Head - pathology
Femur Head Necrosis - diagnostic imaging
Femur Head Necrosis - drug therapy
FGF
Fibroblast Growth Factor 2 - therapeutic use
Follow-Up Studies
gelatin
growth factor
Humans
hydrogel
Hydrogels
Medical prognosis
osteonecrosis of the femoral head
Pain
Prospective Studies
Recombinant Proteins - therapeutic use
Software
Surgery
Survival analysis
Therapy
Treatment Outcome
X-rays
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the 5-year outcomes from the prospective study of recombinant human FGF-2 (rhFGF-2) for osteonecrosis of the femoral head (ONFH). Ten patients (average age 39.8 years) with nontraumatic, precollapse ONFH were percutaneously administered with 800 μg rhFGF-2 contained in gelatin hydrogel. Radiological changes and the prevalidated Harris hip score (HHS), visual analogue scale for pain and University of California, Los Angeles activity-rating scale scoring systems were evaluated. The 5-year comparison in type C2 showed higher joint preservation in the rhFGF-2 group (71.4%) than in the natural course group (15.4%). Two of three clinical scores (Harris hip score and visual analogue scale for pain) improved significantly. Postoperative MRI demonstrated significant reduction in ONFH size. There were no adverse events. rhFGF-2 treatment for ONFH appears to be safe and effective and may have the potential to prevent disease progression.
ISSN:1746-0751
1746-076X
DOI:10.2217/rme-2020-0148